Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
Ankyra and Jenga Bio Announce Exclusive License Agreement for JEN-101
Ankyra Announces First Patient Dosed in Phase 1 Trial Evaluating ANK-101
Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models
Ankyra Announces Trial Agreement with Regeneron to Evaluate ANK-101
Ankyra Receives FDA IND and Health Canada CTA Approval to Advance ANK-101
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical stage biotechnology company developing a new class of anchored immunotherapies to treat cancer, today presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma. The study is being conducted at the University of Illinois College of Veterinary Medicine. Timothy Fan, DVM, PhD, a professor of veterinary clinical medicine and Associate Director for Translation and Development at the Cancer Center at the University of Illinois, is the principal investigator. Dr. Fan presented findings in an oral session during the annual Veterinary Cancer Society conference in Reno, NV.
Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
BOSTON--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for cytokine drugs, announced today that it will be presenting data from a canine clinical trial of cANK-101 at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, FL.
Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer